Latest Cost Restructuring News

Excite Technology Services has raised $2.1 million through convertible notes from institutional investors, including key backer Belgravia Strategic Equities, to fund cost restructuring and operational improvements.

MC Mining Limited has appointed Yi (Christine) He as its permanent Managing Director and CEO, cementing leadership ahead of key coal production milestones at the Makhado Project.

RPMGlobal Holdings clarifies the reasons behind withdrawing its FY2025 earnings guidance following the divestment of its Advisory business, providing detailed updates on software segment performance and compliance with ASX disclosure rules.

DGL Group Limited has issued a corrected FY25 financial presentation, revealing lower EBITDA and NPAT figures due to operational challenges and restructuring costs. Despite revenue growth, the company faces a modified audit opinion on inventory and outlines strategic cost-cutting and growth investments.

Atomos Ltd reported a 9% revenue decline to $32.7 million for FY25 but improved its loss after tax by 35%, driven by cost restructuring and tighter expense control amid challenging market conditions.

BSA Limited reported a 65% drop in net profit for FY2025 despite a 12% revenue increase, driven by the loss of key contracts and a significant operational overhaul. The company faces near-term unprofitable trading but maintains a strong cash position as it reshapes its business.

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.

Xref Limited reported a significantly reduced net loss for FY2025 and a return to positive EBITDA, driven by strategic cost restructuring and a transition to a SaaS business model.

IDP Education’s FY25 results reveal a 14% revenue decline amid a 29% drop in student placement volumes, but strong price growth and cost discipline underpin a multi-year transformation aimed at future profitability.

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.

MyEco Group has secured $1.6 million through unsecured convertible notes to support a strategic operational restructure aimed at reducing costs and scaling production. This capital raise complements existing cash reserves and aims to improve margins while minimising shareholder dilution.

Maggie Beer Holdings reports a sales increase for 1H FY25 but faces declining EBITDA, prompting a strategic overhaul focused on cost reduction and operational streamlining.